News

New Horizons For Measles-Based Vaccines And Therapies

Vienna (Austria), 15 September 2016 – Social Event and
Pre-Symposium Dinner, 14 September
Starting at 16:00

AGENDA

TOPIC 1

Setting the stage:
Viral vectors and global challenges

9:00 - 9:20: Christian Mandl
"History of Viral Vectors - current opportunities and challenges"

9:20 - 9:50: Scott Weaver
"Emerging Viral Infections: West Nile, Chikungunya, Zika ... how can we prepare?"

9:50 - 10:20 Erich Tauber
"Rapid development of new vaccines against Chikungunya and Zika using measles vaccine vectors"


Coffee Break (20 min)


TOPIC 2

Molecular biology and host immune response:
challenges, opportunities and new insights

10:40 - 11:10: Frederic Tangy
"History of measles vector and discovery of its utility in human vaccination"

11:10 - 11:40: Diane Griffin
"Persistence of measles virus RNA and vaccine boosting of immune responses in nonhuman primates and humans"

11:40 - 12:10: Roberto Cattaneo
"Structural and functional determinants of measles virus tropism"


Lunch Break (1 hr)


TOPIC 3

Rapid Response and Emerging infections
The roles of Big Pharma, Biotech, Public and Private Funders

13:10 - 14:00: Podium Discussion


Coffee Break (30 min)


TOPIC 4

Measles vectors as a broad platform

14:30 - 15:00: Michael Muehlebach
"Exploring novel vaccine targets"

15:00 - 15:30: Steve Russell
"Preclinical and clinical experience with oncolytic measles approaches"


TOPIC 5

Translation of Basic Research into
Clinical Vaccine Candidates
The roles of Academia, Biotech, Big Pharma and Funders

15:30 - 16:30 Podium Discussion


MEETING CONCLUSION

16:30 - 16:45: Gerd Zettlmeissl
"Conclusions and Farewell"

CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS

more

Themis Establishes Scientific Advisory Board of Experts in Virology and Vaccine Development

more

Themis Raises EUR 10 Million in Series C Financing to Advance Clinical Pipeline

more

Themis to Present Phase 2 Interim Results for Chikungunya Vaccine Candidate at ASTMH 2017 Annual Meeting

more

Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK

more

Chikungunya-Fever: Themis Bioscience Starts Phase II Clinical Study in Endemic Area

more

NIH and Themis Bioscience Announce the Initiation of a Clinical Trial of a Chikungunya Vaccine

more

Zika Virus: Themis Bioscience Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine

more

Zika Virus: Top EU-Groups Join Forces in Quest for Vaccine. Themis Measles Vector Technology Central to Action Plan

more

Themis Bioscience Successfully Closes 10 M EUR Financing Round

more

Zika Vaccine Development Receives Big Boost by Innovate UK

more

Interview W24/Zika

more

New worldwide, exclusive license agreement provides broad access to Institut Pasteur's virus vector technology – Zika vaccine development progressing with high priority.

more

Two renowned Vaccine Experts Joining Themis Bioscience GmbH

more

Themis Bioscience’s Raises up to EUR 10 Million in Series B New Board to drive partnerships and commercialization of product pipeline

more